TROPION-Lung05 trial of Dato-DXd in NSCLC with actionable mutations. Promising activity (ORR 35%, mPFS 5.4 months), toxicity consistent with prior reports (stomatitis, nausea, ocular tox, ILD). Trop2 H-score not associated with the activity of Dato-DXd. ascopubs.org/doi/10.1200/JC…

🧬 Breaking the VHL/CRBN Duopoly & Ditching the Linker Most PROTACs rely on VHL or CRBN. This paper rewrites the rules. By exploiting native N-degron biology (e.g. Proline → GID4), the authors create potent, linker-free, oral degraders. PROTACs at 500 Da? It’s happening. 🔗

Not just endpoints. Turning points. After median 9 years: NIVO+IPI shows durable OS, PFS & DOR superiority vs sunitinib in 1L aRCC. Robert Motzer MD #ASCO25 #cancer #oncology @oncoalert ASCO Kate Sears Toni Choueiri, MD Emre Yekedüz Neeraj Agarwal, MD, FASCO 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 silke gillessen

Interesting phase 2 trial of 1L taxol/atezo/beva for (mostly) PDL1- mTNBC (n=100) out in Nature Medicine. ORR 63%, mPFS 11 months, mOS 27 months. VEGF inhibition is SO back in breast oncology. Glad to have had the chance to review this paper. nature.com/articles/s4159…

📢 On June 3, 2025, Darolutamide received its FDA approval for de novo metastatic castration-sensitive prostate cancer (mCSPC). To mark this milestone, we created this comprehensive infographic: ✅ All modern AR pathway inhibitors now approved for mCSPC 📉 10-year FDA timeline

Meta-analysis of compression therapy for prevention of chemotherapy-induced peripheral neuropathy ➡️included paclitaxel based treatments ✅Beneficial ⁦⁦Cristiane D Bergerot ⁦MASCC⁩ ⁦OncoAlert ⁩ #cancer #oncology #MedX link.springer.com/article/10.100…

🧪 Menin Inhibitors @ EHA 2025: 🔹 Ziftomenib (Kura/Kyowa): CRc: 94% (1L); ORR: 35–67% 🔹 Revumenib (Syndax): ORR up to 88%; DoR: 13 mo ⚠️ AEs: TRAEs 24–91% 📄 NDA/approvals progressing

For readers interested in bispecific antibodies in oncology, here's a comprehensive review nature.com/articles/s4157… rdcu.be/eqxm5

Now that Taletrectinib is approved by @usfda for metastatic NSCLC Check out the comparison of data for three ROS-1 inhibitors, entrectinib , repotrectinib and Taletrectinib. Useful for quick summary of data for all 3 . Rami Manochakian MD, FASCO Cancer Education OncoAlert Oncology Brothers Kate Sears

🎯 Too many targets. Too little time. ⏳ On June 11, 2025, Taletrectinib received FDA approval for advanced ROS1+ NSCLC. With impressive ORR and CNS activity, it reshapes the ROS1 landscape. 🧠 To keep track of all genetically driven NSCLC therapies, we created this clean,

The potential of the siRNA drug platform is currently being discussed at a session at #BIO2025 - for readers interested in RNAi-based drug design and future directions of the field, here's a comprehensive review nature.com/articles/s4157… rdcu.be/erBXS

Great questions. We conducted a separate analysis of outcomes post-T-DXd by MBC subtype, presented at #SABCS24 and currently under review. We found that SG does not work that well after T-DXd (rwPFS ≤ 3 months), irrespective of intermediate chemo vs. sequenced immediately.

🧬 A rare & inherited cancer, finally getting attention. 📌 18 June 25 NEJM presents: Bevacizumab + Erlotinib in HLRCC-related pRCC 🔹 ORR: 72% 🔹 Median PFS: 21.1 mo 🔹 Median OS: 44.6 mo 🔗 nejm.org/doi/full/10.10… A breakthrough in an ultra-rare, treatment-resistant

This news article has more on apitegromab and its potential in spinal muscular atrophy, as well as obesity, for which positive phase 2 data preserving muscle mass in combination with the GLP-1-based drug tirzepatide was released this week nature.com/articles/d4157…

This should be required reading by all graduate students and postdocs | A brief guide to statistical analysis of grouped data in preclinical research nature.com/articles/s4225…

🎯 HER2 in metastatic UC: It's complicated. 🧬 In 226 pts, ctDNA revealed ERBB2 mutations/amplifications in 16%, vs. 29% in tissue, vs. 55% IHC+. Concordance? IHC vs DNA: 64% ctDNA vs tissue DNA: 87% High heterogeneity. One test isn’t enough?? ctDNA + IHC = better HER2 insight

🆕 FDA grants accelerated approval to Dato-DXd for EGFR-mutated NSCLC post-TKI + chemo 👏 But what’s the full picture? 🤔🧵 🔹 Based on 117 pts pooled from TROPION-Lung01 & Lung05 🔹 ORR: 43% | PFS: 5.8 mo | OS: 15.6 mo 📊 🔹 Prior osimertinib in 82% of pts 🔹 Common tox:

🚨 FDA Accelerated Approval (June 23, 2025) Datopotamab deruxtecan (Datroway) approved for adults with EGFR-mutated NSCLC post EGFR-TKI + platinum chemotherapy ➡️ORR: 45% ⏳ DOR: 6.5 mo 📌 Pooled from TROPION-Lung01 & Lung05 ⚠️ ILD/pneumonitis, stomatitis, ocular AEs included

Association of KRAS variants with survival and therapeutic outcomes in biliary tract cancers ESMO Open doi.org/10.1016/j.esmo… 👉KRAS variants were significantly associated with poor prognosis 🧐We need to better understand the predictive & prognostic implications of GAs in BTC

🚨 #Lungcancer survival has more than doubled. New real-world data from France shows 3-year survival for lung adenocarcinoma rose from 16.3% (2000) to 38.6% (2020) driven by earlier diagnosis & targeted treatment. This is what progress looks like. But it must reach everyone who